In-depth evaluation of the efficacy of efgartigimod: What is the true effect?

Efgartigimod, trade name Vyvgart, is an innovative treatment drug specifically designed to improve the symptoms of patients with generalized myasthenia gravis (gMG). Generalized myasthenia gravis is a rare autoimmune disease in which the patient's immune system mistakenly attacks acetylcholine receptors at the neuromuscular junction, resulting in muscle weakness, fatigue and reduced exercise capacity, seriously affecting the patient's quality of daily life.

Igamod showed significant efficacy in a pivotal clinical study involving129 patients with myasthenia gravis and anti-acetylcholine receptor autoantibodies. The study used the Myasthenia Gravis-Specific Activities of Daily Living (MG-ADL) scale to objectively assess treatment effectiveness. The MG-ADL scale is a specially designed tool to quantify the impact of myasthenia gravis on patients' daily activities. The scale ranges from 0 to 24 points, with higher scores indicating more severe symptoms and more limitations in daily activities.

Results of the study showed that after receiving the first cycle of treatment, approximately68% of the patients in the igamod treatment group had a decrease in MG-ADL score of at least 2 points, which indicates that their symptoms have been significantly improved and their ability to perform daily activities has been enhanced. In comparison, only about 30% of patients who received a placebo saw their MG-ADL scores drop by the same amount. This significant difference not only demonstrates Vyvgart's effectiveness in treating generalized myasthenia gravis, but also highlights its potential to improve patients' quality of life.

In addition, igamod has good safety and tolerability, with relatively mild side effects reported by patients during use, and most patients are able to tolerate it and continue treatment. This makes igamod a reliable and effective treatment option for patients with generalized myasthenia gravis, giving them new hope and opportunities for relief.

Reference link:https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart